Ascendia

  MARKET NEWS

MetrioPharm Receives Orphan Drug Designation for the Treatment of Duchenne Muscular Dystrophy
Silo Pharma Commences Study of Novel Joint Homing Peptide SPU-21
LIXTE Biotechnology’s Lead Clinical Compound Increases Effectiveness of Cancer Immunotherapy
Catalent Adds New Cryogenic Capabilities at Shiga, Japan, Facility to Support Clinical Supply Demand for Cell & Gene Therapy Development
Apellis Reports Top-Line Results from Phase 2 MERIDIAN Study in ALS
Antabio Announces First Subjects Dosed in Phase 1 Clinical Trial of  Highly Differentiated Antibiotic for Severe Hospital Infections

  FEATURED EDITORIAL

  COMPANY PROFILE

Celanese works closely with you as a strategic partner to create innovative controlled-release dosage forms for biologics, small molecules, and RNA to meet the goals of patient-centric therapies, improved medicine and better healthcare economics. Our scientists and engineers are there from concept to commercialization, providing development services, material supply aligned with GMP principles and regulatory support through the Celanese Development & Feasibility Lab. Our objective is to help our customers reduce R&D time and improve the likelihood of successful drug commercialization. Click here for more.

  EXCLUSIVE ONLINE CONTENT

OLON Enters ADC Market

OLON Enters ADC Market

OLON Group recently announced the start of construction of a new facility at its Rodano site (Milan, Italy) which will be entirely dedicated to managing and producing Ultra-Potent compounds, used for example as payloads and payload-linkers for antibody-drug conjugates (ADCs), one of the….

Transgene & BioInvent Report Positive Phase 1a Data on Oncolytic Virus BT-001 in Solid Tumors

Transgene & BioInvent Report Positive Phase 1a Data on Oncolytic Virus BT-001 in Solid Tumors

Transgene and BioInvent International AB recently announce positive Phase 1a data on the oncolytic virus BT-001 for the treatment of solid tumors. Treatment with single agent BT-001 in 18 patients has now been….

Oxford BioTherapeutics & Boehringer Ingelheim Agree on 2-Year Extension to their Second Multi-Year Collaboration in Cancer Immunology

Oxford BioTherapeutics & Boehringer Ingelheim Agree on 2-Year Extension to their Second Multi-Year Collaboration in Cancer Immunology

Oxford BioTherapeutics Ltd. recently announced it has extended its second multi-year collaboration with Boehringer Ingelheim for an additional 2 years. With this extension, further programs will….

Viridian Therapeutics Announces Partnership With Drug Delivery Innovator Enable Injections

Viridian Therapeutics Announces Partnership With Drug Delivery Innovator Enable Injections

Viridian Therapeutics, Inc. recently announced a new partnership with Enable Injections, a company developing and manufacturing the enFuse innovative wearable drug delivery system for….

  WHITEPAPERS & WEBINARS

ON-DEMAND WEBINAR – Solve Common Design Challenges in Inhalation Devices With Porous Polymers

ON-DEMAND WEBINAR – Solve Common Design Challenges in Inhalation Devices With Porous Polymers

The effectiveness of inhalation devices relies on their ability to deliver the pharmaceutical directly to the targeted part of the body with precision and calculated dosing.  Since these devices….

ON-DEMAND WEBINAR - CMC Strategy to Take Bispecifics From DNA to IND in 13 Months* by Lonza

ON-DEMAND WEBINAR - CMC Strategy to Take Bispecifics From DNA to IND in 13 Months* by Lonza

Lonza has applied it’s 35 years of CMC experience in Biologics to develop an end-to-end comprehensive DS/DP DNA to IND strategy in 13 months. This presentation….

  WHITEPAPERS & WEBINARS

APPLICATION NOTE: Process Optimization & Preclinical Production Using the ANP System

APPLICATION NOTE: Process Optimization & Preclinical Production Using the ANP System

Particle Works is thrilled to announce the launch of a new Application Note that delves into the advancement of nanoparticles as carriers for targeted drug delivery. Developing nanoparticles for this purpose can be intricate and demanding, necessitating consistent, cost-effective, and …

TECH BRIEF – Expedite FDA Approvals With Certified Pure Materials

TECH BRIEF – Expedite FDA Approvals With Certified Pure Materials

A key focus of the U.S. Food and Drug Administration’s evaluation of a medical device’s safety and effectiveness is reviewing its material makeup. If improperly tested – and impure materials are used – there is an elevated risk of contamination …

WHITEPAPER - How to Mitigate Risk for Biologics During Fill/Finish Manufacturing

WHITEPAPER - How to Mitigate Risk for Biologics During Fill/Finish Manufacturing

Aseptic processing with the highest degree of sterility assurance, filling accuracy, and quality is critical for high-value, small-batch therapies. This white paper explores the specialized equipment, expertise, and services needed for efficient biologics fill/finish manufacturing.

CLICK HERE TO DOWNLOAD/VIEW THE …

WHITEPAPER - Extrusion-Spheronization, Engineered for Today’s Controlled Release Forms

WHITEPAPER - Extrusion-Spheronization, Engineered for Today’s Controlled Release Forms

 

Synchronizing and controlling API delivery, Extrusion-Spheronization (E-S) offers pharmaceutical drug developers a robust technique to develop and manufacture today’s most complex oral sold dose therapeutics.

Manufacturing oral solid dose API’s into spheres via Extrusion-Spheronization is not new. What is …

  DRUG DEVELOPMENT DIRECT RESOURCES

Upcoming eNewsletter Features:

June 7 – Prefilled Syringes
June 14 – Inhalation Delivery